VENT-04 / Ventus Therap - LARVOL DELTA

Ventus Therapeutics Announces Nomination of VENT-04, a First-in-Class, Oral, Small-Molecule Caspase-4/5 Inhibitor, as a Development Candidate (Businesswire) - "Caspase-4/5 activation is intrinsic to dysbiosis, bacteria-induced IL-18 expression, and pyroptotic cell death, which are all adverse factors in diseases of high unmet need, including inflammatory bowel disease (IBD), hidradenitis suppurativa (HS), severe asthma, and chronic obstructive pulmonary disease (COPD)....In preclinical studies, VENT-04 demonstrated the ability to completely protect mice from gut barrier disruption and robustly inhibited the downstream inflammatory cascade, including clinically validated effectors of disease such as TNF-α and LCN2."

Pipeline update • Preclinical • Asthma • Chronic Obstructive Pulmonary Disease • Hidradenitis Suppurativa • Inflammatory Bowel Disease